Allergic conjunctivitis

Disease ID:1193
Name:Allergic conjunctivitis
Associated with:0 target
8 immuno-relevant ligands
Description
Chronic inflammation of the conjunctiva involing red, itchy, and watery eyes caused by exposure to an allergen or irritant.
Database Links
Disease Ontology: DOID:11204

Targets

No target related data available for Allergic conjunctivitis

Ligands

Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical comments
olopatadine
Immuno Disease Comments: Approved drug for allergic conjunctivitis.
Clinical Use: Olopatadine is contained in opthalmic solutions used to treat the symptoms of seasonal allergic conjunctivitis, including itching, redness and swelling. | View clinical data
Bioactivity Comments: We have been unable to find publicly available affinity data for this drug at its proposed molecular target to substantiate its MMOA, and have therefore not tagged a primary drug target. | View biological activity
lodoxamide
Immuno Disease Comments: Approved drug for allergic (non-infectious) occular inflammation.
Clinical Use: Lodoxamide is used in opthalmic solutions to treat occular inflammation (keratitis or conjunctivitis) caused by the allergic response. | View clinical data
Bioactivity Comments: The precise mechanism of acton/primary molecular target of mast cell stabilizers is not fully resolved, so we have not associated any protein targets with this drug.
Lodoxamide inhibits the migration of THP-1 cells in vitro, in a GPR35-dependent manner [3]. | View biological activity
fluorometholone
Immuno Disease Comments: A topically applied corticosteroid used to treat inflammatory conjunctivitis.
Clinical Use: Fluorometholone is used to treat inflammatory conjunctivitis. | View clinical data
loteprednol etabonate
Immuno Disease Comments: A corticosteroid used to treat ocular inflammation.
Clinical Use: Used to treat eye swelling caused by surgery, infection, allergies, and other conditions. | View clinical data
diphenylpyraline
Immuno Disease Comments: Antihistamine approved for allergic conjunctivitis
Clinical Use: Diphenylpyraline is an antihistamine used to treat allergic rhinitis, hay fever, and allergic skin disorders. There is no information regarding approval for clinical use of this drug on the US FDA website. Other national approval agencies may have granted marketing authorisation. | View clinical data
Bioactivity Comments: We have been unable to find publicly available affinity data for this drug at its proposed molecular target to substantiate its MMOA, and have therefore not tagged a primary drug target. | View biological activity
alcaftadine
Immuno Disease Comments: Approved drug for allergic conjunctivitis.
Clinical Use: Used in an opthalmic solution to treat the symptoms of allergic conjunctivitis. | View clinical data
Bioactivity Comments: We have been unable to find publicly available affinity data for this drug at its proposed molecular target to substantiate its MMOA, and have therefore not tagged a primary drug target. | View biological activity
cromoglicic acid
Immuno Disease Comments: Mast cell stabiliser used to treat allergic conjunctivitis.
Clinical Use: Cromoglicic acid is available in different formulations; nasal spray is used to treat allergic rhinitis, nebulizer solution to treat asthma, eye drops to treat allergic conjunctivitis and an oral form to treat mastocytosis,dermatographic urticaria and ulcerative colitis.
Recent reports suggest that cromolyn inhibits glycogen synthase kinase 3β and may therefore have potential to treat diabetes and obesity [2] and may prove effective in treating insulin-induced lipoatrophy [4]. | View clinical data
Bioactivity Comments: As the precise MMOA of this drug has not been fully resolved, we have not tagged a primary drug target in this case. | View biological activity
navamepent
Immuno Disease Comments: Phase 2 clinical trial NCT01639846 has been completed.
Clinical Use: Phase 2 trials in dry eye syndrome (keratoconjunctivitis sicca), allergic conjunctivitis, and inflammation and pain following cataract surgery have been completed. | View clinical data
Bioactivity Comments: Bioactivity with respect to effects on occular tissues and occular inflammation in model animals is reported in US20140275247A1, but no target interaction is specified [1]. | View biological activity

References

Show »

1. Gjorstrup P, Schwartz CE. (2016) Compositions and methods for the treatment of inflammation. Patent number: US20140275247A1. Assignee: ANIDA PHARMA Inc. Priority date: 13/04/2013. Publication date: 19/04/2016.

2. Motawi TM, Bustanji Y, El-Maraghy SA, Taha MO, Al Ghussein MA. (2013) Naproxen and cromolyn as new glycogen synthase kinase 3β inhibitors for amelioration of diabetes and obesity: an investigation by docking simulation and subsequent in vitro/in vivo biochemical evaluation. J. Biochem. Mol. Toxicol., 27 (9): 425-36. [PMID:23784744]

3. Park SJ, Lee SJ, Nam SY, Im DS. (2018) GPR35 mediates lodoxamide-induced migration inhibitory response but not CXCL17-induced migration stimulatory response in THP-1 cells; is GPR35 a receptor for CXCL17?. Br. J. Pharmacol., 175 (1): 154-161. [PMID:29068046]

4. Phua EJ, Lopez X, Ramus J, Goldfine AB. (2013) Cromolyn sodium for insulin-induced lipoatrophy: old drug, new use. Diabetes Care, 36 (12): e204-5. [PMID:24265375]